Navigation Links
BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
Date:11/22/2011

PRINCETON, New Jersey, November 22, 2011 /PRNewswire/ --

CitiusTech announced today that its BI-Clinical platform for healthcare business intelligence and advanced analytics supports all ACO quality measures that are part of the ACO final rule released by CMS on October 20, 2011.

BI-Clinical can now help ACO participants assess and report performance and quality of care, across all four domains - patient / caregiver experience, care coordination / patient safety, preventive health and at-risk population. With customizable interfaces, gaps-in-care reports, clinical alerts and comparative care-cost benchmarking, BI-Clinical enables ACOs to effectively manage quality of care for its patients, at both the individual as well as population level. BI-Clinical's flexible Clinical Measure Processing Engine enables ACOs to modify clinical measures and create new measures to effectively manage performance.

Dennis Swarup, Business Director at CitiusTech, highlighted, "Most ACOs will include hospitals with different EMRs, clinical applications, revenue cycle applications and financial systems. BI-Clinical's ability to support both claim and EHR data in a multi-vendor environment is key to addressing the ACOs' cross-enterprise reporting and performance management needs."

BI-Clinical has strong professional services partners across North America, who enable ACO participants to define their overall BI/analytics and reporting strategy for all stakeholders. Our partners also implement BI-Clinical and integrate the platform with ACO and hospital IT environments.

About BI-Clinical

CitiusTech's BI-Clinical is a modular, scalable and interoperable platform for healthcare BI, analytics and regulatory compliance. With over 600 pre-built measures and KPIs for clinical, financial, operational and regulatory reporting, BI-Clinical ensures 100% coverage of all Meaningful Use, PQRS, HEDIS, JCAHO and ACO quality reporting measures. BI-Clinical 10.3 is the ONLY modular BI solution that is ONC-ATCB 2011/2012 certified for ALL Eligible Hospital (EH) and Eligible Professional (EP) Meaningful Use criteria. BI-Clinical has strong professional services partnerships in North America. To know more about BI-Clinical and our professional services partners visit http://www.citiustech.com/bi-clinical

About CitiusTech

CitiusTech (http://www.citiustech.com) is a specialist provider of healthcare consulting and technology services to healthcare IT vendors, healthcare providers, health plans, disease management organizations, IDNs, Managed Care Organizations and Accountable Care Organizations. CitiusTech's key offerings include healthcare software engineering, QA/test automation, healthcare BI & analytics, technology consulting and platform-based professional services. CitiusTech's ability to bring strong domain expertise across healthcare technologies, applications and healthcare standards, together with world-class service quality and a global resource base, enables it to offer a distinctive value proposition to its clients.

For more information:
Manager Corporate Marketing
CitiusTech Inc.
sujay.pal@citiustech.com
Tel: +1-877-248-4871



'/>"/>
SOURCE CitiusTech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
2. Ultrathin flexible brain implant offers unique look at seizures in NIH-funded research
3. New report offers broad approach to assessing impacts of ecological damage
4. Evolution offers clues to leading cause of death during childbirth
5. Fiery volcano offers geologic glimpse into land that time forgot
6. Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users
7. Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform™ That Offers Unparalleled Flexibility to End-Users
8. New technology offers the next generation of mammography
9. New class of stem cell-like cells discovered offers possibility for spinal cord repair
10. Novel drug combination offers therapeutic promise for hard-to-treat cancers
11. Research offers means to detoxify mycotoxin-contaminated grain intended for ethanol, animal feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: